Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2024 01:30 ET | Source: Atsena Therapeutics

Nippon Shinyaku and Atsena Therapeutics enter into an Exclusive Strategic Collaboration for ATSN-101 in the U.S. and Japan

KYOTO, Japan and DURHAM, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; President, Toru Nakai) and Atsena Therapeutics, Inc. (Atsena;...
October 10, 2024 07:30 ET | Source: Atsena Therapeutics

Atsena Therapeutics to Present ATSN-201 Safety and Efficacy Data at the American Academy of Ophthalmology 2024 Annual Meeting

DURHAM, N.C., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
September 24, 2024 07:30 ET | Source: Atsena Therapeutics

Atsena Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference

DURHAM, N.C., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
September 17, 2024 07:30 ET | Source: Atsena Therapeutics

Atsena Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis

DURHAM, N.C., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
September 05, 2024 18:30 ET | Source: Atsena Therapeutics

Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase I/II Clinical Trial of ATSN-101 in LCA1 Published in The Lancet

First time patients with LCA1 have been treated with gene therapy ATSN-101 demonstrated durable, clinically significant improvements in vision at the high dose and was well-tolerated 12 months...
August 14, 2024 07:30 ET | Source: Atsena Therapeutics

Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis

Priority Review Voucher would be issued upon approval of ATSN-201 Second RPD and potential PRV for Atsena’s ocular gene therapy portfolio DURHAM, N.C., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Atsena...
July 15, 2024 07:30 ET | Source: Atsena Therapeutics

Atsena Therapeutics Appoints Joseph S. Zakrzewski as Board Chair

DURHAM, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
May 01, 2024 07:30 ET | Source: Atsena Therapeutics

Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)

Subretinal injection of ATSN-201 was well tolerated in all patients in the first cohort with extensive resolution of schisis observed in two patients Provides evidence that AAV.SPR spreads laterally...
March 13, 2024 07:30 ET | Source: Atsena Therapeutics

Atsena Therapeutics Announces Initiation of Dosing in Second Cohort of Phase I/II Clinical Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)

Subretinal injection of ATSN-201 was well tolerated in all patients in first cohort with no serious adverse events reported Enrollment is ongoing in first clinical trial utilizing AAV.SPR, the...
January 16, 2024 07:30 ET | Source: Atsena Therapeutics

Atsena Therapeutics Receives Rare Pediatric Disease Designation from FDA for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)

DURHAM, N.C., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...